Pliant Therapeutics/$PLRX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Pliant Therapeutics

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.

Ticker

$PLRX
Sector
Health
Primary listing
NASDAQ

Employees

49
Headquarters
South San Francisco, United States
Website
pliantrx.com

PLRX Metrics

BasicAdvanced
$77m
-
-$1.84
-
-

What the Analysts think about PLRX

Analyst ratings (Buy, Hold, Sell) for Pliant Therapeutics stock.

PLRX Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37bn
-39.75%
Net income
$45bn
107.52%
Profit margin
37.65%
6.78%

PLRX Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PLRX

Sign up or log in to buy
Capital at risk
Market openLow-cap

Upcoming events

No upcoming events
FAQs